Search
Panitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalThis drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]
DS-2325a
go.drugbank.com/drugs/DB18134InvestigationalDS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Bleomycin
go.drugbank.com/drugs/DB00290ApprovedInvestigationalIt inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Products: BLEOMICINA 15 U VIAL, BLEOLEM 15 IU LIYOFILIZE TOZEtravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalIn 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development … On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg.
Proflavine
go.drugbank.com/drugs/DB01123ApprovedInvestigationalTopical antiseptic used mainly in wound dressings.
Grazoprevir
go.drugbank.com/drugs/DB11575Approvedin combination with [DB11574] for genotypes 1a, 1b, and 4 of Hepatitis C [A19593]. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy
Tolazoline
go.drugbank.com/drugs/DB00797ApprovedVet approvedWithdrawnIt is used in treatment of persistent pulmonary hypertension of the newborn. … A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output.
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.
Seletracetam
go.drugbank.com/drugs/DB05885InvestigationalAs of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam. … Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007.